Most families chose comfort as the primary GOC. 4 key findings →
Participants: 302 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Palliative care is related to reduced life-sustaining treatments for patients with dementia. 3 key findings →
Design: cohort study Participants: 1,996 Evidence: moderate
Full summary, score breakdown and related studies → Original source
67/100
A Systematic ReviewObstructive sleep apnoea, positive airway pressure treatment and postoperative delirium: protocol for a retrospective observational studyEvidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensusDeprescribiendo para mejorar la salud de las personas o cuando deprescribir puede ser la mejor medicinaThe use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational studyNeed for Comprehensive Health Care Quality Measures for Older AdultsDevelopment and initial validation of prescribing quality indicators for patients with chronic kidney diseaseOlder patients' prescriptions screening in the community pharmacy: development of the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP³S) toolA New Computer-Based Tool to Reduce Potentially Inappropriate Prescriptions in Hospitalized Geriatric PatientsThe Successful Aging After Elective Surgery Study: Cohort Description and Data Quality ProceduresRoutine deprescribing of chronic medications to combat polypharmacyAnnual Cognitive Assessment for Older Adults: Update for NursesThe impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysisAssessing appropriateness of osteoarthritis care using quality indicators: a systematic reviewCurrent Factors of Fragility and Delirium in Vascular SurgeryDrug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologistPrescription of potentially inappropriate drugs for geriatric patients in long-term care: improvement through pharmacist's interventionChanging practice in dementia care in the community: developing and testing evidence-based interventions, from timely diagnosis to end of life (EVIDEM)High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA)Delirium in elderly peopleDelphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care UnitsPotentiality of STOPP/START criteria used in primary care to effectively change inappropriate prescribing in elderly patientsToo Much to ManageHip Fracture ManagementAppropriateness of Medication Prescribing Using the STOPP/START Criteria in Veterans Receiving Home-Based Primary CareActualización de la neumonía en el ancianoEstablishi 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Questionably beneficial medications are common in advanced dementia, even as death approaches. 5 key findings →
Design: cohort study Participants: 323 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl D-aspartate receptor antagonist memantine. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Patients continue to receive medications that are not prescribed as symptomatic treatment despite having a LLE. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
For evaluating factors associated with POLST-discordant care, the outcome was ICU admission contrary to POLST order for medical interventions during the last hospitalization of life. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The study revealed a higher prevalence of treatment preference discussions and surrogate appointments in the two northern compared to the two southern European countries. 5 key findings →
Design: cross-sectional Participants: 4,396 Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with dementia with BD had a higher prevalence of comorbidities, greater use of comedications, and greater healthcare utilization and costs than patients with dementia without BD. 5 key findings →
Participants: 103,402 Evidence: low
Full summary, score breakdown and related studies → Original source
Pain and agitation were common and frequently persisted in residents with dementia during nursing home stay, but symptom management intensified only at the end of life. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Pneumonia is a common terminal event in advanced dementia for which many patients receive parenteral antibiotics. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Residents dying with advanced dementia who received SNF care in the last 90 days of life had fewer aggressive treatments and lower odds of hospital death if they also received hospice care at any point during that time. 3 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
53/100
A high level of drug utilization, influenced by the characteristics of residents and the institution, was observed in Belgian nursing homes. 2 key findings →
Design: cross-sectional Participants: 2,510 Evidence: low
Full summary, score breakdown and related studies → Original source
People continue to receive disease-focused therapies at the end of life rather than therapies exclusively for palliation of symptoms, suggesting that treatments may vary according to the person's primary diagnosis. 2 key findings →
Design: cross-sectional Participants: 2,623 Evidence: low
Full summary, score breakdown and related studies → Original source
Irrespective of antibiotic treatment, pneumonia causes substantial suffering in demented patients. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
This cohort study examines the use of cholinesterase inhibitors and memantine among older adults with dementia after admission into hospice care despite the medications’ limited clinical benefit following enrollment into hospice. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 5406 nursing home residents with advanced dementia, 2911 (53.9%) received at least 1 medication with questionable benefit (range, 44.7% in the Mid-Atlantic census region to 65.0% in the West South Central census region). 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Among the elderly, prestroke dementia is a powerful independent predictor of in-hospital mortality after acute reperfusion therapy for stroke. 2 key findings →
Participants: 153 Evidence: low
Full summary, score breakdown and related studies → Original source
On average, surveyed caregivers (n = 431) were 78.3 years, had 16 years of education, and were mainly White (88.5%). 5 key findings →
Design: cross-sectional Participants: 431 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A program that limits the extent of medical treatment in patients with advanced dementia of the Alzheimer type was initiated on an intermediate medical ward. 1 key finding →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
Fever episodes in 104 institutionalized patients with Alzheimer's disease were prospectively evaluated to determine the impact of antibiotic treatment on fever outcomes. 3 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
Eighty-two percent of recommendations were successfully implemented during hospitalization and included in the discharge plan. 4 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
In interviews PWD were able to indicate their treatment preferences across all three scenarios. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
We aimed to explore diagnoses associated with antipsychotic use, treatment patterns and characteristics of users without diagnoses relevant to antipsychotic treatment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Incurably ill patients often receive nonpalliative interventions at the end of life. 3 key findings →
Participants: 164 Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events